Creative Planning’s Astria Therapeutics ATXS Stock Holding History

Creative Planning’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,786	Closed	-$298K	–	4097
2025 Q4	$298K	Buy	+22,786	New	+$272K	﹤0.01%	3242
2025 Q2	–	Sell	-10,959	Closed	-$58.5K	–	3686
2025 Q1	$58.5K	Buy	10,959 +10,862	+11,198%	+$76K	﹤0.01%	3329
2024 Q4	$867	Buy	+97	New	+$1.03K	﹤0.01%	3549
2020 Q4	–	Sell	-5,253	Closed	-$195K	–	2349
2020 Q3	$195K	Buy	+5,253	New	+$208K	﹤0.01%	1691
2017 Q1	–	Sell	-17	Closed	-$4K	–	4642
2016 Q4	$4K	Buy	+17	New	+$4.16K	﹤0.01%	4032

Creative Planning's ATXS Position: Q1 2026 in Review

Creative Planning sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 22,786 shares — an estimated $298K sold.

Creative Planning first reported a position in ATXS in Q4 2016 and held it in 5 quarters. The position peaked at $298K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Creative Planning reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Creative Planning sold 22,786 Astria Therapeutics shares in Q1 2026, an estimated $298K.
Creative Planning first reported a position in Astria Therapeutics in Q4 2016 and held it in 5 quarters.
Creative Planning's Astria Therapeutics position peaked at $298K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.